Coley Fluid was a mainstream cancer therapy for many years, but its use particularly in the United States declined with the advent of chemotherapy. In 1962, an amendment to the Pure Food and Drug Act established the present system of FDA approval. The amendment included a “grandfather clause” that legalized drugs currently being marketed. Unfortunately, in 1962 no U.S. companies were marketing Coley Fluid so in spite of a 70-year history of safe and effective use, beginning in 1962 Coley Fluid was no longer an approved therapy in the United States.

In 1982, researchers determined 5-year survival of historical Coley Fluid cancer patients was equivalent to 5-year survival of modern patients. In 1999, researchers found 10-year survival of historical Coley Fluid patients was better than modern sarcoma, kidney and ovarian cancer patients. In addition to prolonging survival, Coley Fluid was frequently curative in types of cancer that are incurable today.

Coley Fluid is known by many different names: Coley Vaccine, Coley’s Toxins, Coley’s Mixed Toxin, Coley’s Mixture, Erysipelas and Prodigiosis Toxins, Febrivax, Multi Bacterial Vaccine, and Vaccineurin.

MBVax Bioscience provides Coley Fluid for research and clinical study.